


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/692,105	
				Filing Date	October 23, 2003	
				First Named Inventor	Bradley, et al.	
				Art Unit	1654 1655	
				Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	B185 1015.1 (MSC 8009.5)	
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
mcf	P1	US-4,115,551	09-19-78	Lormeau, et al.		
	P2	US-5,096,637	03-17-92	DiLeo, et al.		
	P3	US-5,237,050	08-17-93	Boyle, et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
mcf	F1	EP 0 399 321 A2	11-28-90	Miles, Inc.		
	F2	GB 904,478	08-29-62	American Cyanamid Co.		
	F3	JP 0207 8633	03-19-90	The Green Cross Corp.		
	F4	WO 95 04077 A1	02-09-95	The Green Cross Corp.		
Examiner Signature	<i>Michelle C. Neal</i>			Date Considered	12/22/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 27 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 7/31/2006. OMB 0651-0031

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				<i>Complete if Known</i>	
				Application Number	10/692,105
				Filing Date	October 23, 2003
				First Named Inventor	Bradley, et al.
				Art Unit	1654 1655
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	B185 1015.1 (MSC 8009.5)


NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Michele C. Floyd	Date Considered	12/22/2006
-----------------------	------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



EV 336 697 723 US

Sheet 1 of 1

Form PTO-1449 & TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. B185 1015.1	Serial No. 10/692,105
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		Applicant Bradley, et al.		
		Filing Date October 23, 2003	Group 1654 1655	

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
mct	P1	4,259,448	1981	Nakamura, et al.	435	215	

FOREIGN PATENT DOCUMENTS

mct	F1	CN 1 167 823 A	1997	Huang, C.	—	—	
	F2	JP 09 065895 A	1997	Nitto Boseki Co., Ltd.	—	—	
	F3	RO 103 682 A	1991	Cantacuzino Inst Bucuresti	—	—	
	F4	WO 93/15189 A	1993	Consiglio Nazionale Ricerche	—	—	
▼	F5	WO 87/06836 A	1987	Emory University	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

mct	D1	Binder, B.R., et al., "Purification and Characterization of Human Vascular Plasminogen Activator Derived from Blood Vessel Perfusates," <i>Journal of Biological Chemistry</i> , 254(6): 1998-2003 (1979).
	D2	Castellino, F.J., et al., "Rabbit Plasminogen and Plasmin Isozymes," <i>Methods in Enzymology</i> , 45: 273-286 (1976).
	D3	Robbins, K.C., et al., "Human Plasminogen and Plasmin," <i>Methods in Enzymology</i> , 19: 184-199 (1970).
	D4	INTERNATIONAL SEARCH REPORT (PCT/US03/34020, dated 27 July 2004).
	D5	EUROPEAN SUPPLEMENTARY PARTIAL SEARCH REPORT (EP 00 97 8572, dated 16 July 2004).
	D6	EUROPEAN SUPPLEMENTARY PARTIAL SEARCH REPORT (EP 00 99 1956, dated 01 June 2004).
▼	D7	EUROPEAN SUPPLEMENTARY PARTIAL SEARCH REPORT (EP 00 99 0910, dated 25 May 2004).

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:	DATE CONSIDERED:
<i>Michelle C. Flood</i>	<i>12/22/2006</i>



EL 984 914 472 US
Sheet 1 of 3

FORM 1449-1449		Attorney Docket No. B185 1015.1	Serial No. 10/692,105
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Applicant Bradley, et al.	
		Filing Date October 23, 2003	Group 1654 1655

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
MC7	P1	6,479,253	11/2002	Silver, et al.	—	—	
	P2	6,139,819	10/31/00	Unger, et al.	—	—	
	P3	5,879,923	3/9/99	Yago, et al.	—	—	
	P4	5,776,452	7/7/98	Eibl, et al.	—	—	
	P5	5,767,269	6/1998	Hirsh, et al.	—	—	
	P6	5,728,674	1998	Sprecher, et al.	—	—	
	P7	5,472,692	12/5/95	Liu, et al.	—	—	
	P8	5,407,673	1995	Reich, et al.	—	—	
	P9	5,328,996	7/1994	Boyle	—	—	
	P10	5,304,383	4/19/94	Eibl, et al.	—	—	
	P11	5,290,692	3/1994	Suzuki, et al.	—	—	
	P12	5,288,489	2/1994	Reich, et al.	—	—	
	P13	5,165,912	11/1992	Selmer, et al.	—	—	
	P14	5,024,829	6/1991	Berger, et al.	—	—	
	P15	4,908,204	3/1990	Robinson, et al.	—	—	
	P16	4,774,087	9/1988	Wu, et al.	—	—	
	P17	4,663,146	5/1987	Morser, et al.	—	—	
	P18	4,462,980	7/1984	Diedrichsen, et al.	—	—	
	P19	4,446,316	5/1984	Chazov, et al.	—	—	
	P20	4,442,213	4/1984	Heber, et al.	—	—	
	P21	4,361,653	11/1982	Watanabe, et al.	—	—	
	P22	4,361,652	11/1982	Uemura, et al.	—	—	
	P23	4,177,262	12/1979	Lormeau, et al.	—	—	
	P24	4,082,612	04/1978	Robbins, et al.	—	—	
	P25	3,950,513	04/1976	Jensen	—	—	
▼	P26	3,434,929	03/1969	Buck, et al.	—	—	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
mc3	F1	EP 0256836 A1	08/87	EPO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

mc3	D1	Ambrus, C., <i>et al.</i> , "Insolubilized Activators of the Fibrinolysis System," <i>J. Med.</i> 3: 270-281 (1972).
	D2	Ambrus, J.L., <i>et al.</i> , "Clinical Pharmacology of various types of fibrinolytic enzyme preparations," <i>Am. J. Cardiol.</i> , 6:462-475 (1960).
	D3	Amris, C.J., <i>et al.</i> , "Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer," <i>Danish Medical Bulletin</i> , 11(5): 141-145 (1964).
	D4	Amris, C.J., <i>et al.</i> , "Turnover and Distribution of ¹³¹ I-Labelled Procine Plasmin in Man and Dog," <i>Danish Medical Bulletin</i> , 11(5): 146-152 (1964).
	D5	Anlyan, W., <i>et al.</i> , "Experiences with Fibrinolysis in Peripheral Vascular Occlusive Disease," <i>Am. J. Cardiol.</i> , 6: 507-512 (1960).
	D6	Barrett, A.J., <i>et al.</i> , "The Electrophoretically 'Slow' and 'Fast' Forms of the α_2 -Macroglobulin Molecule," <i>Biochem. J.</i> , 181: 401-418 (1979).
	D7	Boucek, R., <i>et al.</i> , "Segmental Perfusion of the Coronary Arteries with Fibrinolysis in Man Following a Myocardial Infarction," <i>Am. J. Cardiol.</i> , 6: 525-533 (1960).
	D8	Boyles, P.W., <i>et al.</i> , "Comparative effectiveness of intravenous and intra-arterial fibrinolysis therapy," <i>Am. J. Cardiol.</i> , 6: 439-446 (1960).
	D9	Castellino, F.J. and J.R. Powell, "Human Plasminogen," <i>Meth. Enzymology</i> , 80: 365-378 (1981).
	D10	Collen, D., <i>et al.</i> , "Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration," <i>J. of Clin. Invest.</i> , 71(2): 368-376 (1983).
	D11	Deutsch, D.G. and E.T. Mertz, "Plasminogen: purification from human plasma by affinity chromatography," <i>Science</i> 170: 1095-1096 (1970).
	D12	Freitag, H., <i>et al.</i> , "Lys-plasminogen as an Adjunct to Local Intra-arterial Fibrinolysis of Carotid Territory Stroke: Laboratory and Clinical Findings," <i>Neuroradiology</i> , 38: 181-185 (1996).
	D13	Hedner, U., <i>et al.</i> , "Effects of Porcine Plasmin on the Coagulation and Fibrinolytic Systems in Humans," <i>Blood</i> , 51(1): 157-164 (1978).
	D14	Kitamoto, Y., <i>et al.</i> , "A Femoral Vein Catheter with Immobilized Urokinase (UKFC) as an Antithrombotic Blood Access," <i>Trans. Am. Soc. Artif. Intern. Organs</i> , 33: 136-139 (1987).
	D15	Larsen, V., "Fibrinolytic Enzyme in the Treatment of Patients with Cancer," <i>Danish Medical Bulletin</i> , 2(5): 137-140 (1964).
	D16	Larson, V., <i>et al.</i> , "Fibrinolytic Treatment with Activator-Free Porcine Plasmin," <i>Scand. J. Clin. Invest.</i> 18(Suppl. 89): 34-73 (1966).
	D17	Lijnen, H.R., <i>et al.</i> , "Activation of plasminogen by pro-urokinase," <i>J. Biol. Chem.</i> , 261(1): 1253-1258 (1986).
↓	D18	Lippschutz, E.L., <i>et al.</i> , "Controlled study of the treatment of coronary occlusion with urokinase-activated human plasmin," <i>Am. J. Cardiol.</i> , 16:93-98 (1965).

MC7	D19	Moser, K., "Effects of Intravenous Administration of Fibrinolysis (Plasmin) in Man," <i>Circulation</i> , 20: 42-55 (1959).
	D20	Mizutani <i>et al.</i> "Potential thrombolysis under selective infusion of autolotous plasmin (AP) solution," <i>Japanese Heart Journal</i> , 30(5): 723-732 (1989).
	D21	Nilsson, T. and B. Wiman, "On the structure of the stable complex between plasmin and alpha-2-antiplasmin," <i>FEBS Lett.</i> , 142(1): 111-114 (1982).
	D22	Novokhatny, V. <i>et al.</i> "Thrombolytic potential of locally delivered active plasmin (Pm): In vitro assessment and in vivo comparison with tPA in the rabbit jugular vein thrombosis model," <i>Blood, J. of the Am. Soc. of Hematology</i> , 92(10) Suppl. 2, Abstract 3400. (Nov. 15, 1998).
	D23	Robbins, K.C. and L. Summaria, "Plasminogen and Plasmin," <i>Meth. Enzymol.</i> 45: 257-273 (1976).
	D24	Robbins, K.C., <i>et al.</i> , "Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on Diethylaminoethyl-Sephadex, <i>The Journal of Biological Chemistry</i> , 238(3): 952-962 (1963).
	D25	Sherry, S., "The Origin of Thrombolytic Therapy," <i>J. Am. Coll. Cardiol.</i> , 14(4): 1085-1092 (1989).
	D26	Verstraete, M., "The Fibrinolytic System: from Petri Dishes to Genetic Engineering," <i>Thrombosis and Haemostasis</i> , 74(1): 25-35 (1995).
→	D27	Wiman, B., "Affinity-chromatographic purification of human alpha 2-antiplasmin," <i>Biochem. J.</i> , 191(1): 229-232 (1980).

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE: <i>Michelle C. Ward</i>	DATE CONSIDERED: <i>12/22/2006</i>
--	---------------------------------------